Trazodone is one of the most commonly prescribed medications for insomnia, but the evidence behind it is surprisingly mixed. It reliably reduces the number of times you wake up during the night, and it increases deep sleep, but meta-analyses show it does not significantly improve total sleep time, how quickly you fall asleep, or overall sleep efficiency compared to placebo. That gap between its popularity and its clinical evidence is worth understanding before you start or continue taking it.
What Trazodone Does in the Brain
Trazodone was originally developed as an antidepressant, but at the low doses used for sleep (typically 25 to 150 mg), it works differently than it does at full antidepressant doses. At these lower doses, it blocks three types of receptors involved in keeping you awake: serotonin receptors that regulate arousal, histamine receptors (the same ones targeted by drugs like Benadryl), and adrenaline-related receptors that play a role in alertness. Blocking all three simultaneously dampens your brain’s wakefulness signals from multiple directions at once, which is why it makes most people feel drowsy within 30 to 60 minutes of taking it.
Its half-life follows a two-phase pattern. The initial phase lasts about 3 to 6 hours, and the slower terminal phase lasts 5 to 9 hours. This means its strongest sedative effect hits in the first few hours, which helps with falling asleep, but enough of the drug remains active to reduce middle-of-the-night awakenings.
What the Clinical Evidence Actually Shows
The most consistent finding across studies is that trazodone reduces the number of times you wake up during the night compared to placebo. A meta-analysis reviewed by the American Academy of Family Physicians found a statistically significant decrease in nightly awakenings, with a moderate effect size. People taking trazodone also tend to report that their sleep feels better quality subjectively.
However, when researchers measure sleep with objective tools rather than patient reports, the results are less impressive. Total sleep time, sleep efficiency (the percentage of time in bed that you’re actually asleep), how long it takes to fall asleep, and time spent awake after initially falling asleep did not show significant improvement over placebo in pooled analyses. This doesn’t mean trazodone does nothing. It means the benefits are more about sleep continuity and perceived quality than about adding large chunks of extra sleep time.
How It Affects Sleep Stages
One area where trazodone performs well is deep sleep. In a study using polysomnography (overnight sleep monitoring), patients on trazodone saw their deep sleep percentage increase from about 10.6% to 15.4% of total sleep time. Deep sleep is the stage most important for physical recovery and memory consolidation, so this is a meaningful benefit. The time spent in lighter, less restorative sleep decreased correspondingly.
Trazodone also leaves REM sleep largely intact. In the same study, REM sleep stayed essentially unchanged (around 14 to 15% of total sleep). This matters because some other sleep medications, particularly older ones, suppress REM sleep, which can affect dreaming, emotional processing, and how rested you feel the next day.
How It Compares to Other Sleep Medications
Compared to zolpidem (Ambien), trazodone reduces sleep latency by a similar amount, but zolpidem is generally more effective at producing full remission of insomnia and improving daytime functioning, including reducing fatigue and mental fog. Zolpidem works faster and more reliably for people who need rapid relief.
The tradeoff is safety. Zolpidem carries real risks with prolonged use: tolerance, dependence, rebound insomnia when you stop, memory problems, and in older adults, increased rates of falls, fractures, delirium, and cognitive decline. Trazodone does not cause dependence or tolerance to the same degree, does not produce rebound insomnia when discontinued, and does not cause the memory impairment associated with zolpidem. For people who need a longer-term option, particularly older adults, trazodone’s safety profile gives it a practical advantage even if its raw efficacy is lower.
One limitation worth noting: because trazodone is technically an antidepressant, its full effects on sleep may take up to four weeks to develop due to how serotonin systems adjust over time. If you need immediate relief from severe insomnia, this slower onset can be frustrating.
What Sleep Medicine Guidelines Say
Despite being one of the most prescribed sleep aids in the United States, trazodone does not have a strong endorsement from professional sleep organizations. The American Academy of Sleep Medicine issued a weak recommendation suggesting clinicians not use trazodone for sleep onset or sleep maintenance insomnia. “Weak” in guideline language means the evidence is limited or conflicting rather than that the drug is harmful. The recommendation reflects the gap between trazodone’s widespread real-world use and the relatively thin body of rigorous clinical trial data supporting it.
Much of trazodone’s use for insomnia is off-label. It was never formally approved for this purpose by the FDA, which means pharmaceutical companies never ran the large-scale trials that would be required for approval. The studies that do exist tend to be small, short in duration, and sometimes focused on specific populations like patients with depression or dementia rather than otherwise healthy people with insomnia.
Typical Dosing for Sleep
When prescribed for insomnia, trazodone is started at 25 to 50 mg taken at bedtime, well below the 150 to 400 mg range used for depression. The dose can be increased up to 200 mg for sleep if needed. Most people find their effective dose somewhere between 50 and 100 mg. Because the sedative effect comes from receptor blocking that occurs at low doses, going higher doesn’t always mean better sleep. It mainly adds side effects.
Side Effects and Risks
The most common side effects at sleep doses are morning grogginess, dry mouth, dizziness, and lightheadedness, especially when standing up quickly. The dizziness comes from the same adrenaline receptor blocking that helps with sleep, since it also lowers blood pressure slightly.
The most notable rare side effect is priapism, a prolonged and painful erection unrelated to arousal, which occurs in an estimated 1 in 1,000 to 1 in 10,000 male patients. Most cases happen within the first month of starting the medication. Priapism is a medical emergency that requires immediate treatment, so anyone experiencing an erection lasting more than four hours should seek urgent care.
Long-term safety data for trazodone as a sleep aid is limited. There have not been large studies specifically tracking outcomes in people taking low-dose trazodone for insomnia over years. What is known is reassuring in that trazodone does not appear to cause the dependence, withdrawal, or cognitive decline seen with benzodiazepines and drugs like zolpidem. But the absence of long-term data is itself a gap worth acknowledging.
Who Benefits Most
Trazodone tends to work best for people whose main sleep problem is frequent awakenings rather than difficulty falling asleep in the first place. If you fall asleep fine but wake up repeatedly at 2 or 3 a.m., trazodone’s strengths align well with your problem. It also has a natural advantage for people with both insomnia and anxiety or depression, since its serotonin activity can address mood symptoms alongside sleep, even at low doses.
For people who have tried cognitive behavioral therapy for insomnia (the first-line treatment recommended by most guidelines) and still need pharmacological help, trazodone offers a reasonable option with fewer long-term risks than most alternatives. Its real-world track record is decades long, even if the clinical trial data hasn’t fully caught up. Many clinicians prescribe it precisely because it works “well enough” for many patients without the baggage of dependence or next-day impairment that comes with stronger sleep medications.